Two Sigma Investments’s Candel Therapeutics CADL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$266K Sell
25,470
-7,261
-22% -$80.5K ﹤0.01% 4414
2026
Q2
$337K Sell
32,731
-60,769
-65% -$459K ﹤0.01% 4452
2026
Q1
$458K Sell
93,500
-5,700
-6% -$31K ﹤0.01% 3789
2025
Q4
$560K Sell
99,200
-36,916
-27% -$199K ﹤0.01% 3242
2025
Q3
$694K Sell
136,116
-233,079
-63% -$1.35M ﹤0.01% 2813
2025
Q2
$1.87M Buy
+369,195
New +$1.9M ﹤0.01% 1882
2024
Q2
– Sell
-13,409
Closed -$21.2K – 3052
2024
Q1
$21.2K Buy
+13,409
New +$19.9K ﹤0.01% 2926

Other funds holding CADL

Two Sigma Investments's CADL Position: Q3 2026 in Review

Two Sigma Investments reduced its Candel Therapeutics (CADL) stake by 22% in Q3 2026, selling an estimated $80.5K and leaving 25,470 shares worth $266K. The position accounts for ﹤0.01% of the portfolio, ranked #4414.

Two Sigma Investments first reported a position in CADL in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.87M in Q2 2025. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Two Sigma Investments held 25,470 shares of Candel Therapeutics worth $266K as of Q3 2026.
  • Two Sigma Investments sold 7,261 Candel Therapeutics shares in Q3 2026, an estimated $80.5K.
  • Candel Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q3 2026, its #4414 holding.
  • Two Sigma Investments first reported a position in Candel Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Two Sigma Investments's Candel Therapeutics position peaked at $1.87M in Q2 2025.
  • 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Two Sigma Investments's 13F filing for Q3 2026, filed 16 Nov 2026.